2,266 press releases in English indexed under biotech & pharma.
Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative therapies for the treatment of complement-related conditions and oncology, today announced that members of senior management will participate in the Maxim Growth Summit 2026 on Wednesday, October 14, 2026 in New York.
VANCOUVER, British Columbia, Oct. 09, 2026 -- Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage biotechnology company leveraging its proprietary Diffusphere™ technology designed to optimize local, controlled drug delivery for applications with significant unmet need, today is pleased to announce that three abstracts related to Company’s ongoing Phase 1b/2 RESOLVE trial of EP-104GI for the treatment of eosinophilic esophagitis ("EoE") have been accepted and will be presented at: (i) the American College of Gastroenterology (ACG) 2026 Annual Scientific Meeting & Postgraduate Course, being held October 9-14, 2026 in Nashville, Tennessee, and (ii) the United European Gastroenterology (UEG) Week 2026, being held October 17-20, 2026 in Barcelona, Spain.
Company common stock to trade on Nasdaq under the symbol “IRLA” effective October 12, 2026
Filana Therapeutics, Inc. (NASDAQ: FLNA, "Filana Therapeutics", the "Company"), a biotechnology company currently focused on developing therapies for the treatment of Tuberous Sclerosis Complex (TSC)-related epilepsy, today announced that the Company’s management team will participate in the 2026 Maxim Growth Summit being held October 12-14, 2026 in New York.
Eli Lilly and Company (NYSE: LLY) today announced new exploratory data from the TOGETHER-PsO Phase 3b clinical trial evaluating the concomitant use...
Uro-oncology treatments encompass a range of therapeutic approaches aimed at addressing cancers of the urinary system, including the bladder, kidneys, and prostate.
· Achieved Global Milestone with Mass Graphology Campaign for Indian Medical Fraternity · An initiative celebrating clinicians’ selfless service and personal traits India’s leading global pharmaceutical manufacturer, Cadila Pharmaceuticals, has been officially recognized by the Asia Book of Records. This prestigious recognition follows a nationwide doctor engagement initiative that facilitated a handwriting analysis study involving […]
Maximize ROI through biomarker-led therapies, priority-market expansion, optimized resource allocation, and strategic co-development or acquisitions Maximize ROI through biomarker-led therapies, priority-market expansion, optimized resource allocation, and strategic co-development or acquisitions
NGS Leads as Precision Medicine, Oncology and NIPT Adoption Accelerates, While Long-Read Sequencing, AI Bioinformatics and Pharma Partnerships Unlock Opportunities NGS Leads as Precision Medicine, Oncology and NIPT Adoption Accelerates, While Long-Read Sequencing, AI Bioinformatics and Pharma Partnerships Unlock Opportunities
In a head-to-head Phase 3 trial, prifemilast nearly doubled the rate of PASI 75 response compared with apremilast and achieved superiority on both co-primary endpoints Results support the potential of prifemilast to deliver greater efficacy than apremilast, with low rates of serious...
New Phase 3 Data Demonstrates Envudeucitinib Rapidly and Durably Improved Psoriasis Burden Across Scalp, Itch, and Quality of Life Measures
How quality, supply resilience, manufacturing excellence and innovation are supporting the next generation of biologics. MILAN, Oct. 9, 2026 -- Europe's biologics sector is expanding as ageing populations and the rising burden of chronic, autoimmune and rare diseases increase...